Энанорм

Quick links to important sections

Энанорм

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Энанорм

What is Enanorm?

Enanorm is a combination pharmaceutical product used in the management of cardiovascular health. It belongs to a class of medications known as fixed-dose combinations, meaning it contains two different active pharmacological agents within a single tablet. These components work through different physiological pathways to help regulate blood pressure.

Composition and Active Ingredients

The effectiveness of Enanorm is derived from its two primary components:

  • Enalapril: This is an ACE (Angiotensin-Converting Enzyme) inhibitor. It works by interfering with the production of certain natural substances that cause blood vessels to tighten, thereby allowing the vessels to relax and widen.
  • Nitrendipine: This is a calcium channel blocker belonging to the dihydropyridine group. It acts by inhibiting the entry of calcium ions into the smooth muscle cells of the blood vessels, which leads to vasodilation and reduced peripheral vascular resistance.

Mechanism of Action

Enanorm utilizes a dual-action approach. While the enalapril component addresses the hormonal regulation of blood pressure via the renin-angiotensin-aldosterone system, the nitrendipine component acts directly on the physical tension of the vascular walls. By combining these two mechanisms, the medication aims to provide a more comprehensive effect on systemic blood pressure than either component might achieve alone at similar doses.

Clinical Purpose

The primary objective of this combination therapy is the management of essential hypertension (high blood pressure). It is typically considered when a patient’s blood pressure is not sufficiently controlled by a single medication, or when a healthcare professional determines that a combination of an ACE inhibitor and a calcium channel blocker is appropriate for the patient's specific clinical profile.

Regulatory References

  1. WHO Essential Medicines List (EML)
  2. WHO Essential Medicines List
  3. NIH/NCBI StatPearls Review on Enalapril

What side effects are possible with Энанорм?

Possible side effects and safety information

The safety profile of Энанорм (enalapril maleate), an Angiotensin-Converting Enzyme (ACE) inhibitor, is officially classified by regulatory authorities based on the frequency and system-organ class of reported adverse reactions. This classification includes effects ranging from very common to rare, as documented in official prescribing information.

Frequency-Classified Adverse Reactions

The most frequently reported effects, listed as Very Common or Common in regulatory labels, include headache, dizziness, cough, and fatigue. Symptomatic hypotension (low blood pressure) is also common and is noted to be most likely at the initiation of therapy or following dose adjustment. Hyperkalaemia (increased serum potassium) and renal impairment are also classified as common findings.

Classification Example Adverse Reactions (Regulatory Terminology)
Very Common Headache, Dizziness, Cough, Fatigue
Common Symptomatic Hypotension, Angioedema, Hyperkalaemia
Uncommon Vomiting, Pancreatitis, Urticaria, Vertigo

Serious Adverse Reactions and Safety Constraints

The official label highlights several clinically significant, though typically rare, serious adverse reactions. The most critical is Angioedema, which involves swelling of the face, extremities, lips, tongue, or larynx and may occur at any time during treatment. Other rare but serious reactions include hepatic failure, jaundice, and certain blood disorders.

Population-specific safety constraints are mandated, most notably the contraindication in pregnancy due to a defined risk of fetal toxicity, injury, and death when the medication is used during the second and third trimesters. Furthermore, specific caution is required for patients with renal impairment, necessitating monitoring of kidney function and serum electrolytes.

Overdose and Emergency Response

Overdose and When to Seek Help

The most prominent manifestation of an overdose with enalapril is an exaggerated pharmacological effect leading to profound hypotension (extremely low blood pressure). Officially documented clinical signs associated with this severe drop include dizziness, confusion, stupor, and episodes of fainting (syncope). This severe hemodynamic crisis can escalate to life-threatening outcomes, including circulatory shock and the development of acute renal impairment or failure. Secondary severe complications, such as myocardial infarction or cerebrovascular accident, have been documented as possible consequences of sustained, severe hypotension in vulnerable patients.

Required Emergency Actions

Regulatory guidance mandates that individuals seek immediate medical attention and contact emergency services upon any suspicion of overdose or if severe symptoms, such as collapse, are present. Hospitalization and intensive observation are required until vital signs and clinical status are fully stabilized.

Management and Monitoring

Management is officially defined as symptomatic and supportive treatment. While no specific antidote is known for enalapril, the active metabolite, enalaprilat, can be effectively removed by hemodialysis. Required clinical procedures involve volume expansion using intravenous fluids to rapidly correct the hypotension. Monitoring of vital signs, serum electrolytes (due to risk of hyperkalemia), and renal function is necessary. Regulatory documents note that patients with pre-existing renal impairment may experience accumulation of the active metabolite, which could increase overdose severity.

Therapeutic Uses of Энанорм

What Энанорм Treats: Main Uses and Benefits

Энанорм is applied across domains where additional symptomatic support is needed and is often used during phases when symptoms become more noticeable. It is relevant for easing symptoms and supports the patient during difficult episodes, particularly in managing conditions that involve discomfort or heightened physiological activity.

The medication may assist with managing symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms. It is commonly used to help with symptoms related to heightened physiological activity, symptoms that create noticeable functional strain, and manifestations that interfere with daily comfort. Энанорм contributes to improved comfort during periods of heightened symptoms in acute, symptom-driven episodes.


Key Applications & Patient Benefit

Clinical scenarios commonly involve situations requiring temporary assistance in symptom stabilization. The medication is considered relevant for easing specific types of symptoms, often applied during phases of increased distress or discomfort. It may assist with maintaining functional stability when symptoms interfere with routine activities. One key patient benefit is that Энанорм may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Distressing Symptoms

Энанорм is commonly used to help with symptoms that create noticeable functional strain.

Regulatory References

  1. NIH overview of NSAIDs and Analgesics

Eligibility and Restrictions for Use

The official eligibility profile for Энанорм (Enalapril) is strictly defined by regulatory authorities based on age, medical history, physiological status, and concurrent treatments.

Contraindicated Populations

  • Pregnancy: The medicine is contraindicated during the second and third trimesters and must be discontinued immediately upon detection of pregnancy.
  • Angioedema History: Prohibited in patients with a history of swelling of the face, lips, or throat (angioedema) related to previous ACE inhibitor treatment, or in those with hereditary angioedema.
  • Drug Interactions: Contraindicated for use with sacubitril/valsartan (a neprilysin inhibitor); it must not be administered within 36 hours of switching to or from this drug.
  • Aliskiren: Contraindicated in patients with diabetes mellitus who are also taking aliskiren-containing products.

Restricted and Age-Specific Use

Population Status Regulatory Classification Official Restriction Context
Age (Pediatric) Allowed Approved for children mathbfge 1 month of age for hypertension.
Age (Neonates) Not Recommended Not recommended for infants mathbfle 1 month of age due to insufficient data.
Organ Function Conditional Use Patients with impaired renal function require caution, monitoring, and likely initial dose adjustment.
Lactation Not Recommended Advised against use, particularly in mothers of preterm infants or during the first few weeks after delivery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Энанорм (Enalapril), established in government regulatory documentation, is defined by constraints related to dual system blockades and managing electrolyte balance.


Contraindicated Combinations and Timing Rules

Co-administration with Sacubitril/Valsartan (a Neprilysin Inhibitor) is strictly prohibited due to the officially documented risk of angioedema. A mandatory washout period of 36 hours is required between the last dose of Enalapril and the first dose of Sacubitril/Valsartan. Furthermore, the use with Aliskiren or Angiotensin Receptor Blockers (ARBs) is contraindicated in patients with diabetes or moderate-to-severe renal impairment (estimated CrCl < 60 mL/min) as a dual blockade restriction.


Interactions Affecting Electrolytes

The co-administration of Enalapril with potassium-sparing diuretics (such as Spironolactone, Amiloride, or Triamterene) or potassium supplements/salt substitutes is officially documented as having a pharmacodynamic effect that increases the risk of hyperkalemia (elevated serum potassium). This requires close monitoring, particularly in populations with pre-existing renal conditions.


Other Documented Interactions

Enalapril reduces the renal clearance of Lithium, an interaction that increases Lithium exposure and the potential for toxicity. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may officially diminish the drug's blood pressure-lowering effect. Alcohol may potentiate the hypotensive effect. Official labels state that food does not affect the absorption of Enalapril.

Mechanism of Action

How Энанорм Works — Mechanism of Action

Энанорм exerts its pharmacodynamic action through a dual-antagonist mechanism centered on the signaling pathways that coordinate the emetic reflex. Its primary action is a selective antagonism of the 5-HT3 receptors, which are fast-acting, ligand-gated ion channels. The drug targets these receptors on peripheral vagal afferent nerve terminals in the gastrointestinal lining and centrally within the Chemoreceptor Trigger Zone (CTZ).

By blocking serotonin's access to the 5-HT3 receptor, the drug reduces the transmission of initial afferent sensory signals from the gut and decreases the excitability of central reflex centers.

Its secondary, complementary action involves weak antagonism of the D2 dopamine receptors located predominantly in the CTZ. This restricts dopamine-mediated signal transduction in the brainstem's emetic center.

This dual-pathway interference leads to a synergistic suppression of the emetic center's excitability. By modifying these early molecular steps, the mechanism promotes a predictable physiological adjustment by reducing the motor output and reflexive activity of the emetic center, thereby decreasing the downstream physiological consequences of excessive mediator activity.

Dosage and Administration Information

Энанорм (enalapril maleate) is typically administered by the oral route as a tablet or, less commonly, as an oral solution. The active metabolite, enalaprilat, is administered separately as a solution for slow intravenous injection. The primary dosing pattern for adult hypertension begins with 5 mg taken once daily, with subsequent adjustment to a maintenance range generally between 10 and 40 mg per day. For heart failure, the initial oral dose is 2.5 mg once or twice daily. This initial low dose is then subject to a prescribed titration process over several weeks to reach a defined maintenance dose, often 20 mg daily.

Administration Timing and Adjustments

The tablet formulation may be taken with or without food, as absorption is not significantly affected by meal timing. Dosing frequency is usually once daily, but some regimens for heart failure or to prevent the blood pressure-lowering effect from diminishing may involve two divided doses per day. In cases of renal impairment (kidney function changes), standard protocols involve a reduced starting dose of 2.5 mg daily to prevent inappropriate exposure. Similarly, patients on dialysis are instructed to take 2.5 mg on dialysis days, administered after the procedure. If a scheduled dose is missed, patients must not take a double dose to compensate. The intravenous form, administered every six hours, requires a precise, slow infusion time of five minutes or longer.

Recent Clinical Evidence

Research evidence / Overview of Studies for Энанорм


Evidence for Use in Chronic Hypertension (High Blood Pressure)

The research base for the use of Энанорм in managing high blood pressure primarily consists of numerous large-scale Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were structured to monitor changes in both systolic and diastolic blood pressure (BP) levels. Researchers also recorded measurements of cardiovascular events, such as heart attack and stroke, across diverse adult populations. Studies found that data show patterns related to decreases in BP measurements reported in the studies. Large, long-term trials recorded measurements of cardiovascular events occurring in the populations studied compared to control groups.


Evidence for Use in Symptomatic Heart Failure

The research foundation for its use in patients with symptomatic heart failure relies on large, pivotal, placebo-controlled RCTs specifically evaluating patients with reduced left ventricular function. These studies monitored patient outcomes reflecting daily functioning, functional class, total survival, and hospitalization rates due to worsening heart failure. Pivotal long-term trials have monitored differences in survival rates when comparing the studied populations to placebo, and studies reported that the medication was associated with differences in the hospitalization rates for heart failure. The evidence structure is primarily derived from studies involving Heart Failure with Reduced Ejection Fraction (HFrEF).


Evidence for Use in Asymptomatic Left Ventricular Dysfunction

Research examined the use of the drug in adults who showed signs of heart weakness but do not yet have noticeable heart failure symptoms. These were structured as long-term, randomized prevention trials that were designed to monitor the rate at which patients developed overt symptomatic heart failure. Studies examined the rate of progression to symptomatic heart failure in the observed populations and monitored the incidence of death when comparing the groups. The results apply only to the populations studied, which were defined by specific criteria for left ventricular dysfunction.


Research Gaps and Areas of Uncertainty

While the evidence base is substantial, several research limitations remain. Data are still emerging for long-term progression to end-stage renal disease in those with chronic kidney disease (CKD), as most studies rely on indirect laboratory markers. Evidence is also limited for certain specific populations, such as children under six years of age.

Frequently Asked Questions (FAQ)

Common questions about Энанорм (FAQ)

Q: How quickly can a person expect Энанорм to start working?

Official product information states that the effects of oral Энанорм typically begin within one hour of taking a dose. The maximum effect is generally reported to be reached within four to six hours.


Q: How long does the effect of one dose of Энанорм typically last?

Regulatory documents indicate that the effect designed to lower blood pressure is maintained for at least 24 hours in most individuals who take the prescribed dose. This profile supports the convenience of once-daily dosing.


Q: What is the proper way to discontinue the use of Энанорм?

The official documentation does not specify a mandatory schedule for gradually stopping this medication for general patient populations. Decisions regarding stopping the medication are made in consultation with a healthcare provider.


Q: Is Энанорм safe to use during breastfeeding?

Official product information indicates that the use of Энанорм during breastfeeding is not recommended. This cautionary approach is especially recommended when nursing newborn or premature infants, as the active substance has been found in human milk.


Q: What is the general expectation for improvement when using Энанорм?

Studies and official information indicate that for high blood pressure, trials consistently recorded decreases in blood pressure measurements. For heart failure, clinical trials monitored differences in rates of survival and hospitalization when compared to control groups.


Q: What happens if a person stops taking Энанорм suddenly?

Official documents note that when the intravenous form of the active drug was withdrawn abruptly, it was not associated with a rapid increase in blood pressure. Discontinuation of treatment is managed by a healthcare provider.


Q: Does Энанорм need to be taken at the same time every day?

Regulatory documents state the medication is usually prescribed to be taken once daily. While this commonly implies consistency, the official label does not contain an explicit mandate for the time of day.


Q: What are the official restrictions for use of Энанорм?

Restrictions described in official documents include contraindication during the second and third trimesters of pregnancy and in patients with a history of swelling of the face or throat (angioedema) related to previous use of this drug class. It is also contraindicated for use with specific other medications, as listed in the label.


Q: How often do people typically need to take Энанорм?

The required dosing frequency is most often once daily for many authorized uses. However, regulatory documents allow for regimens that involve two divided doses per day, especially when treating heart failure.


Q: What is the main difference between Энанорм and similar drugs?

Энанорм is chemically classified as a prodrug; it is inactive when swallowed and must be converted by the liver into its active form. It is also distinguished from older medications in its class by its long-acting profile, a characteristic that allows for once-daily dosing.


Q: Why is Энанорм used for this specific condition?

This medication is officially indicated for the treatment of hypertension (high blood pressure) and the management of symptomatic heart failure. It is used because its mechanism helps promote the relaxation and widening of blood vessels, reducing the workload on the heart by promoting the relaxation and widening of blood vessels.


Q: Are there any common foods or supplements that might interact with Энанорм?

Official documents note a risk when taken with potassium supplements or certain salt substitutes, as this can lead to elevated potassium levels in the blood. Otherwise, food in general does not affect the absorption of the tablet.


Q: Is it normal to feel a little dizzy when first starting Энанорм?

Yes, regulatory documentation classifies dizziness and a drop in blood pressure (symptomatic hypotension) as common adverse reactions. These effects are noted to be most likely at the initiation of therapy or following a dose adjustment.


Q: Are there any special warnings about driving while taking Энанорм?

Official information advises that the ability to drive or operate machinery may be affected due to potential side effects like dizziness or fatigue. This effect is noted particularly at the start of treatment or when the dose is increased.


Q: Is there a generic version of Энанорм available?

Yes, the active ingredient in Энанорм, enalapril maleate, is widely available in generic formulations that are approved and listed by government regulatory agencies.


Q: Are there any specific times of day that are better for taking Энанорм?

Official instructions confirm that the tablet can be taken with or without food. While the medication is typically dosed once a day, there is no statement in regulatory documents that mandates a specific time of day for optimal effectiveness.


Q: Can the effectiveness of Энанорм be affected by other health conditions?

Yes, official documentation notes that conditions such as changes in kidney function (renal impairment) require careful monitoring and a likely adjustment to the starting dose. Caution is also needed with other heart conditions.


Q: Can Энанорм be used alongside vitamins and minerals?

The official label specifies a known interaction risk with potassium supplements, which can cause high potassium levels. Other vitamins and minerals are not generally listed as critical interactions, but patients are advised to inform their healthcare professional about all supplements used.


Q: Does taking Энанорм require any special monitoring by a doctor?

Yes, official safety constraints mandate that doctors monitor the patient's kidney function and serum electrolytes (potassium levels). This monitoring is especially important when treatment begins or when the dose is changed.


Q: How does Энанорм affect blood pressure?

The drug works by promoting the relaxation and widening of blood vessels (vasodilation). This action reduces the resistance to blood flow, thereby achieving its purpose of lowering high blood pressure.


Q: How is Энанорм different from taking an over-the-counter remedy for the same condition?

Энанорм is a prescription-only drug belonging to the highly specific ACE Inhibitor class, approved for the long-term management of chronic cardiovascular conditions. Over-the-counter remedies are generally not approved or studied for the same long-term treatment goals as this class of prescription medicine.


Q: Are the side effects of Энанорм usually mild or severe?

The adverse reactions in official documents are classified across a spectrum. Effects like dizziness and headache are listed as Very Common and generally considered less serious. However, the label also lists rare but serious adverse reactions, such as angioedema, which require immediate attention.


Q: Can Энанорм affect mood or mental state?

Official adverse reaction reports include uncommon reports of psychiatric or nervous system disturbances such as nervousness or sleep disorders. Very common effects like dizziness and headache are also reported.


Q: Are there any common reasons why a doctor might not prescribe Энанорм?

Yes, common reasons include if a person is in the later stages of pregnancy, has a history of angioedema related to this drug class, or is currently taking certain restricted medications such as sacubitril/valsartan.


Q: Is there a link between Энанорм and stomach discomfort?

Yes, official safety documents report that gastrointestinal issues, including nausea, diarrhea, or abdominal pain, are classified as common to uncommon adverse reactions that have been associated with the medication.

How should Энанорм be stored and disposed of?

How to Store and Dispose of Энанорм?

The official regulatory guidance for Энанорм (Enalapril maleate tablets) specifies strict conditions to maintain product stability and ensure household safety. The medication must be kept at room temperature, generally between 20 C and 25 C (68 F and 77 F). Storing the tablets requires protection from conditions that cause degradation.

Storage Requirement Official Condition
Temperature & Environment Store away from excess heat, moisture, and freezing conditions.
Packaging Keep in the original container and ensure the container is tightly closed.
Safety Keep out of the sight and reach of children.
Disposal Do not use after the expiry date. Consult a pharmacist or a community drug take-back program for disposing of unused or expired medicine; do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Энанорм found in:

A-Z Index: